Asia One1d
Eisai's Corporate Venture Capital Subsidiary, Eisai Innovation, Inc., Selected for AMED's 'Strengthening Program for Pharmaceutical Startup Ecosystem"
Eisai Co., Ltd. and Eisai’s corporate venture capital subsidiary, Eisai Innovation, Inc. announced today that Eisai ...
FierceBiotech12d
Eisai, Eli Lilly didn't disclose heightened brain injury risk to Alzheimer's trial patients: NYT
A new bombshell has been dropped in the scandal-plagued world of Alzheimer’s disease drug development. | Between the two ...
Biogen partner Eisai completes FDA submissions for injectable Alzheimer’s therapy
Eisai (ESAIY) completes BLA submissions for an injectable version of its Biogen (BIIB)-partered Alzheimer's drug Leqembi in ...
Medscape11m
Experts Challenge New Diagnostic Criteria for Alzheimer’s
A group of experts is challenging revised diagnostic criteria for Alzheimer’s disease as laid out by the Alzheimer’s ...
Eisai completes rolling BLA submission for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug ...
What Drugmakers Did Not Tell Volunteers in Alzheimer’s Trials
Genetic tests showed that certain patients were predisposed to brain injuries if they took the drugs. That information ...
GEN17h
Alzheimer’s Drug Shows Slower Cognitive Decline in Lower Tau Patients
After dosing with Cognition’s CT1812, study reports declines of 95% and higher in subgroup with below-median p-tau217.
pharmaphorum1d
Eisai, Biogen eye 2025 approval for Leqembi autoinjector
Eisai and Biogen have completed their rolling biologics license application in the US for a subcutaneous formulation of Alzheimer's disease therapy Leqembi previously delayed by the FDA on ...